
AngioDynamics, Inc.: updates and filings
Price
$11.78
November 16, 2026Market cap $495M
What Ploutos Investor adds for AngioDynamics
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 8, 2026next Jan 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
July 2026
April 2026
February 2026
January 2026
November 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 8, 2026Quarterly reportfor the period to Aug 31, 2026Form10-Q
- Oct 8, 2026Additional annual meeting materialFormDEFA14A
- Oct 8, 2026Annual meeting proxy statementFormDEF 14A
- Oct 8, 2026Results of operations, Regulation FD disclosureForm8-K
- Oct 8, 2026Material agreement entered, officer or director changeForm8-K
- Sep 29, 2026Annual report (amendment)for the period to May 31, 2026Form10-K/A
- Sep 29, 2026Annual report (amendment)for the period to May 31, 2026Form10-K/A
- Jul 14, 2026Annual reportfor the period to May 31, 2026Form10-K
- Jul 14, 2026Results of operations, Regulation FD disclosureForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 23, 2026Other material eventsForm8-K
- Apr 2, 2026Quarterly reportfor the period to Feb 28, 2026Form10-Q
- Apr 2, 2026Results of operations, Regulation FD disclosureForm8-K
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Feb 9, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Feb 3, 2026Officer or director changeForm8-K
- Jan 14, 2026Regulation FD disclosureForm8-K
- Jan 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jan 6, 2026Quarterly reportfor the period to Nov 30, 2025Form10-Q
- Jan 6, 2026Results of operations, Regulation FD disclosureForm8-K
- Nov 14, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2025Shareholder voteForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 8, 2026 | 10-Q | Quarterly reportfor the period to Aug 31, 2026 | Document |
| Oct 8, 2026 | DEFA14A | Additional annual meeting material | Document |
| Oct 8, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Oct 8, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 8, 2026 | 8-K | Material agreement entered, officer or director change | Document |
| Sep 29, 2026 | 10-K/A | Annual report (amendment)for the period to May 31, 2026 | Document |
| Sep 29, 2026 | 10-K/A | Annual report (amendment)for the period to May 31, 2026 | Document |
| Jul 14, 2026 | 10-K | Annual reportfor the period to May 31, 2026 | Document |
| Jul 14, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 23, 2026 | 8-K | Other material events | Document |
| Apr 2, 2026 | 10-Q | Quarterly reportfor the period to Feb 28, 2026 | Document |
| Apr 2, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Feb 9, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Feb 3, 2026 | 8-K | Officer or director change | Document |
| Jan 14, 2026 | 8-K | Regulation FD disclosure | Document |
| Jan 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jan 6, 2026 | 10-Q | Quarterly reportfor the period to Nov 30, 2025 | Document |
| Jan 6, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Nov 14, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2025 | 8-K | Shareholder vote | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 5, 2004.
The full analysis
What do AngioDynamics's filings show?
The filings are where every one of AngioDynamics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.